ERBB2 and breast cancer: As a more comprehensive analysis of the heterogeneous tumor biology, the PAM50 assay was proposed, which analyzes the gene expression of 50 genes in tumor tissue and thus divides breast cancer patients into luminal A, luminal B, HER2-enriched, and basal-like patients by their "intrinsic" subtypes [8].